Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $134.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 17.76% year-over-year to $134.6 million; the trailing twelve-month figure through Mar 2026 stood at $134.6 million (up 17.76% YoY), and the FY2025 full-year result was $149.5 million, up 21.09% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $134.6 million, down from $149.5 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $149.5 million in Q4 2025, with the low at $48.3 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $94.7 million across 5 years, with a median of $95.3 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 97.52% — and 2026, when it gained 17.76%.
• Catalyst Pharmaceuticals' Total Non-Current Liabilities stood at $61.1 million in 2022, then climbed by 29.61% to $79.3 million in 2023, then jumped by 55.79% to $123.5 million in 2024, then advanced by 21.09% to $149.5 million in 2025, then slipped by 9.95% to $134.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $134.6 million (Q1 2026), $149.5 million (Q4 2025), and $131.2 million (Q3 2025), per Business Quant data.